NCT05379946 - Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

DRUG

D-1553

D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation

DRUG

IN10018

IN10018 orally once daily at approximately the same time each day

Trial Locations (1)

310005

Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,, Hangzhou